Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23542739 | 0.82 | NPC1 (0.31) | — | |
| SCHEMBL18254626 | 0.80 | APLNR (0.48) | SMN1; SMN2NOS2KDM4EALDH1A1 | |
| SCHEMBL18252824 | 0.77 | GABRA1 (0.32) | SMN1; SMN2LMNA | |
| SCHEMBL15255480 | 0.75 | LMNA (0.35) | SMN1; SMN2LMNANOS2KDM4EALDH1A1 | |
| SCHEMBL15044982 | 0.75 | NPC1 (0.32) | — | |
| SCHEMBL19756427 | 0.74 | SORD (0.33) | — | |
| SCHEMBL27890771 | 0.73 | NOS2 (0.34) | SMN1; SMN2LMNANOS2KDM4EALDH1A1 | |
| SCHEMBL31737004 | 0.73 | NPC1 (0.31) | — | |
| SCHEMBL15928097 | 0.73 | CHRNA7 (0.32) | — | |
| SCHEMBL19756419 | 0.71 | MEN1 (0.30) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192704-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192704-A1 | MONOCARBOXYLIC ACID TRANSPORTER 4 (MCT4) MODULATORS AND USES THEREOF | SLC16A3, SLC16A1, SLC16A8 | SMN1; SMN2 2868/4885LMNA 3146/4885NOS2 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.